Literature DB >> 10972036

Colonization and transmission of Ureaplasma urealyticum and Mycoplasma hominis from mothers to full and preterm babies by normal vaginal delivery.

K B Chua1, Y F Ngeow, C T Lim, K B Ng, J K Chye.   

Abstract

A prospective study was carried out among pregnant women and their newborn babies in the University Hospital, Kuala Lumpur from January 1996 to June 1997. The maternal cervical colonization rates of Ureaplasma urealyticum (UU) and Mycoplasma hominis (MH) were found to be 57.5% and 15.8% respectively while the isolation rates from nasopharyngeal secretions of the newborns were 50.8% for UU and 6.6% for MH. The overall transmission rates were 88.4% for UU and 42.1% for MH. There was no significant difference in the transmission rates of either organism from mothers to their respective newborn babies by the maturity of pregnancy. In preterm babies, the nasopharyngeal isolation rates of UU and MH were not influenced by the babies' gestational age and birth weight nor by the maternal history of abortion or parity. However, there was a tendency for UU to persist in the nasopharyngeal secretion of preterm babies especially those of birth weight below 2 kg. None of the babies contaminated with mycoplasmas at birth developed respiratory symptoms during six to eight weeks of follow-up.

Entities:  

Mesh:

Year:  1999        PMID: 10972036

Source DB:  PubMed          Journal:  Med J Malaysia        ISSN: 0300-5283


  8 in total

1.  Characterization of ureaplasmas isolated from preterm infants with and without bronchopulmonary dysplasia.

Authors:  Brenda Katz; Padma Patel; Lynn Duffy; Robert L Schelonka; Reed A Dimmitt; Ken B Waites
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 2.  Mycoplasmas and ureaplasmas as neonatal pathogens.

Authors:  Ken B Waites; Brenda Katz; Robert L Schelonka
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

3.  Maternal microbe-specific modulation of inflammatory response in extremely low-gestational-age newborns.

Authors:  Raina N Fichorova; Andrew B Onderdonk; Hidemi Yamamoto; Mary L Delaney; Andrea M DuBois; Elizabeth Allred; Alan Leviton
Journal:  mBio       Date:  2011-01-18       Impact factor: 7.867

4.  Colonization of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women and their transmission to offspring.

Authors:  Behnam Sobouti; Shahrzad Fallah; Mohammadreza Mobayen; Samileh Noorbakhsh; Yaser Ghavami
Journal:  Iran J Microbiol       Date:  2014-08

5.  Ureaplasma Species Differentially Modulate Pro- and Anti-Inflammatory Cytokine Responses in Newborn and Adult Human Monocytes Pushing the State Toward Pro-Inflammation.

Authors:  Kirsten Glaser; Christine Silwedel; Markus Fehrholz; Ana M Waaga-Gasser; Birgit Henrich; Heike Claus; Christian P Speer
Journal:  Front Cell Infect Microbiol       Date:  2017-11-28       Impact factor: 5.293

6.  Perinatal Ureaplasma Exposure Is Associated With Increased Risk of Late Onset Sepsis and Imbalanced Inflammation in Preterm Infants and May Add to Lung Injury.

Authors:  Kirsten Glaser; Anna Gradzka-Luczewska; Marta Szymankiewicz-Breborowicz; Natalia Kawczynska-Leda; Birgit Henrich; Ana Maria Waaga-Gasser; Christian P Speer
Journal:  Front Cell Infect Microbiol       Date:  2019-04-02       Impact factor: 5.293

7.  Pathophysiological and molecular considerations of viral and bacterial infections during maternal-fetal and -neonatal interactions of SARS-CoV-2, Zika, and Mycoplasma infectious diseases.

Authors:  Gonzalo Ferreira; Fernanda Blasina; Marianela Rodríguez Rey; Gabriel Anesetti; Rosana Sapiro; Luisina Chavarría; Romina Cardozo; Grazzia Rey; Luis Sobrevia; Garth L Nicolson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-10-06       Impact factor: 5.187

8.  Adverse pregnancy and birth outcomes associated with Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum: a systematic review and meta-analysis.

Authors:  Marinjho Emely Jonduo; Lisa Michelle Vallely; Handan Wand; Emma Louise Sweeney; Dianne Egli-Gany; John Kaldor; Andrew John Vallely; Nicola Low
Journal:  BMJ Open       Date:  2022-08-26       Impact factor: 3.006

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.